FDA licenses Acambis' ACAM2000 vaccine for protection against smallpox
Acambis developed ACAM2000 under contracts with the US Centers for Disease Control and Prevention (CDC) as part of its preparations for a public health emergency. ACAM2000, which is a single-dose vaccine, is the primary smallpox vaccine for use in an emergency and forms the majority of the US Government's smallpox vaccine Strategic National Stockpile (SNS). To date, Acambis has supplied 192.5 million doses of ACAM2000 to the CDC for the SNS.
Acambis is currently in advanced negotiations with the CDC for a "warm-base manufacturing" contract to provide the US Government with a long-term ACAM2000 production capability that is located entirely in the US. The contract would also cover licence maintenance activities.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.